These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 38820974

  • 1. Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes.
    Fernández-González JF, García-Pedraza JÁ, Terol-Úbeda AC, Martín ML, Morán A, García-Domingo M.
    Biomed Pharmacother; 2024 Jul; 176():116814. PubMed ID: 38820974
    [Abstract] [Full Text] [Related]

  • 2. Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats.
    Fernández-González JF, García-Pedraza JÁ, Marín-Quílez A, Bastida JM, Martín ML, Morán A, García-Domingo M.
    Biomed Pharmacother; 2022 Sep; 153():113276. PubMed ID: 35717784
    [Abstract] [Full Text] [Related]

  • 3. Peripheral 5-HT₁D and 5-HT₇ serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats.
    García-Pedraza JÁ, García M, Martín ML, Gómez-Escudero J, Rodríguez-Barbero A, Román LS, Morán A.
    Eur J Pharmacol; 2013 Aug 15; 714(1-3):65-73. PubMed ID: 23769743
    [Abstract] [Full Text] [Related]

  • 4. Chronic 5-HT2 receptor blockade unmasks the role of 5-HT1F receptors in the inhibition of rat cardioaccelerator sympathetic outflow.
    García-Pedraza JÁ, Hernández-Abreu O, García M, Morán A, Villalón CM.
    Can J Physiol Pharmacol; 2018 Apr 15; 96(4):328-336. PubMed ID: 28886249
    [Abstract] [Full Text] [Related]

  • 5. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway.
    Fernández-González JF, García-Pedraza JÁ, Ordóñez JL, Terol-Úbeda AC, Martín ML, Morán A, García-Domingo M.
    Int J Mol Sci; 2023 Jan 10; 24(2):. PubMed ID: 36674892
    [Abstract] [Full Text] [Related]

  • 6. Blockade of 5-HT2 receptors with sarpogrelate uncovers 5-HT7 receptors inhibiting the tachycardic sympathetic drive in pithed rats.
    Hernández-Abreu OI, García-Pedraza JÁ, Rivera-Mancilla E, Villanueva-Castillo B, Morán A, García-Domingo M, Manrique-Maldonado G, Altamirano-Espinoza AH, Villalón CM.
    Clin Exp Pharmacol Physiol; 2020 Mar 10; 47(3):403-411. PubMed ID: 31846086
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment.
    García-Pedraza JÁ, López C, Fernández-González JF, Martín ML, Morán A, García-Domingo M.
    J Pharmacol Sci; 2021 Sep 10; 147(1):48-57. PubMed ID: 34294372
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes.
    Fouad Shalaby MA, Abd El Latif HA, El Yamani M, Galal MA, Kamal S, Sindi I, Masaood R.
    BMC Pharmacol Toxicol; 2021 Oct 26; 22(1):64. PubMed ID: 34702339
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats.
    García-Pedraza JÁ, García M, Martín ML, San Román L, Morán A.
    Eur J Pharmacol; 2014 May 15; 731():80-7. PubMed ID: 24675150
    [Abstract] [Full Text] [Related]

  • 14. Chronic Sarpogrelate Treatment Reveals 5-HT7 Receptor in the Serotonergic Inhibition of the Rat Vagal Bradycardia.
    García-Pedraza JÁ, García M, Martín ML, Eleno N, Morán A.
    J Cardiovasc Pharmacol; 2017 Jan 15; 69(1):13-22. PubMed ID: 27676327
    [Abstract] [Full Text] [Related]

  • 15. 5-HT modulates the rat mesenteric vasopressor outflow by 5-HT1D sympatholytic receptors.
    García-Pedraza JÁ, García-Domingo M, Gómez-Roso M, Rodríguez-Barbero A, Martín ML, Morán A.
    Clin Exp Pharmacol Physiol; 2017 Dec 15; 44(12):1224-1231. PubMed ID: 28771848
    [Abstract] [Full Text] [Related]

  • 16. Diabetes-induced changes in the 5-hydroxytryptamine inhibitory receptors involved in the pressor effect elicited by sympathetic stimulation in the pithed rat.
    García M, Morán A, Calama E, Martín ML, Barthelmebs M, Román LS.
    Br J Pharmacol; 2005 Jul 15; 145(5):593-601. PubMed ID: 15852039
    [Abstract] [Full Text] [Related]

  • 17. Participation of cyclooxygenase pathway in the vasoconstriction induced by 5-HT in the in situ autoperfused kidney of long-term diabetic rats.
    Restrepo B, García M, Rodríguez-Barbero A, Román LS, Martin ML, Morán A.
    Eur J Pharmacol; 2011 May 20; 659(1):37-44. PubMed ID: 21414306
    [Abstract] [Full Text] [Related]

  • 18. Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats.
    García-Pedraza JÁ, Hernández-Abreu O, Morán A, Carretero J, García-Domingo M, Villalón CM.
    Sci Rep; 2020 Nov 09; 10(1):19358. PubMed ID: 33168874
    [Abstract] [Full Text] [Related]

  • 19. Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats.
    García-Domingo M, García-Pedraza JÁ, Fernández-González JF, López C, Martín ML, Morán A.
    Int J Mol Sci; 2022 May 20; 23(10):. PubMed ID: 35628547
    [Abstract] [Full Text] [Related]

  • 20. Hypertension exhibits 5-HT4 receptor as a modulator of sympathetic neurotransmission in the rat mesenteric vasculature.
    García-Pedraza JÁ, García-Domingo M, Gómez-Roso M, Ruiz-Remolina L, Rodríguez-Barbero A, Martín ML, Morán A.
    Hypertens Res; 2019 May 20; 42(5):618-627. PubMed ID: 30696976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.